HIV antibody characterization as a method to quantify reservoir size during curative interventions.
about
How to Define the Latent Reservoir: Tools of the TradeQuantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy.A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level.Ultrarapid Measurement of Diagnostic Antibodies by Magnetic Capture of Immune ComplexesLuciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases.Select host restriction factors are associated with HIV persistence during antiretroviral therapy.Lack of Evidence for Molecular Mimicry in HIV-Infected Subjects.Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.No Evidence of Antibodies against GAD65 and Other Specific Antigens in Children with Autism.Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral TherapyInternational AIDS Society global scientific strategy: towards an HIV cure 2016.Qualitative and quantitative HIV antibodies and viral reservoir size characterization in vertically infected children with virological suppression.Persistent HIV-1 replication during antiretroviral therapy.HIV Antibody Level as a Marker of HIV Persistence and Low-Level Viral Replication.Detection and monitoring PLA2R autoantibodies by LIPS in membranous nephropathy.Frontline Science: Plasma and immunoglobulin G galactosylation associate with HIV persistence during antiretroviral therapy.Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?
P2860
Q26766705-01DAE44A-DCBC-4509-8E7F-36A4BCB209FEQ33677727-52FC4686-DA54-47FE-9CEF-6288CC7D6A0BQ33745355-C6B3AF50-4944-4B7B-92B7-E86F43DC29DAQ33812635-62966E47-9996-49F0-A573-8913E1870ABBQ35013894-E98BC23E-5F47-4FA9-BE1E-97C810F088DAQ35271996-70DE30B9-86F6-49C8-B7D3-8950AA75E352Q35849605-5BB8296A-B5CA-4F1F-B487-59575121815DQ35929985-DE7B0F28-87B5-4C32-80C0-1D300C3E4346Q36045361-E6970271-E17E-42B5-8662-829D06DC9459Q36092497-7BC23A6E-48B0-4B73-BC6C-857326291C9BQ37661770-9A055E59-7395-4067-AB0F-07898E624026Q38776093-40B9EC06-12EC-48DA-9AC6-70F2095903F7Q38808266-1BCEA5AF-BEF3-41A1-88E1-992A357B357AQ40203692-D360EC30-601D-457E-8736-170979B783CBQ50908320-2E4FF7B6-4EAB-4F50-A335-781890C812E4Q52597179-3AEDD020-B336-4CEF-8D2C-D460CCFCA24CQ52699607-2809AD10-87B8-4910-AF12-DE36A8C60774
P2860
HIV antibody characterization as a method to quantify reservoir size during curative interventions.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
HIV antibody characterization ...... during curative interventions.
@en
HIV antibody characterization ...... during curative interventions.
@nl
type
label
HIV antibody characterization ...... during curative interventions.
@en
HIV antibody characterization ...... during curative interventions.
@nl
prefLabel
HIV antibody characterization ...... during curative interventions.
@en
HIV antibody characterization ...... during curative interventions.
@nl
P2093
P2860
P356
P1476
HIV antibody characterization ...... during curative interventions.
@en
P2093
Ahmad Bayat
Craig S Rhodes
Gero Hütter
Jeffrey N Martin
Joseph A Kovacs
Peter D Burbelo
Rebecca Hoh
Rémi Fromentin
P2860
P304
P356
10.1093/INFDIS/JIT667
P407
P577
2013-11-28T00:00:00Z